Sectors
GYRE
Gyre Therapeutics, Inc.
6.10
1 x 5.96
1 x 6.04
bid
ask
+
0.04
0.71%
10:02 AM
timesize
| Ytd | -13.55% | |
| 1y | -15.58% |
5.97
day range
6.10
5.44
52 week range
9.42
| Open | 6.03 | Prev Close | 6.06 | Low | 5.97 | High | 6.10 | Mkt Cap | 553.83M |
| Vol | 2.42K | Avg Vol | 93.84K | EPS | 0.07 | P/E | 86.57 | Forward P/E | 25.22 |
| Beta | 1.89 | Short Ratio | 21.22 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 6.34 | 200-d Avg | 7.37 | 1yr Est | 0.00 |
| Income Statement | |||
| Total Revenue | 22.52M | ||
| Revenues (USD) | 22.52M | ||
| Cost of Revenue | 1.23M | ||
| Gross Profit | 21.29M | ||
| Operating Expenses | 30.65M | ||
| Research and Development Expense | 6.74M | ||
| Selling, General and Administrative Expense | 21.36M | ||
| Operating Income | -9.35M | ||
| Income Tax Expense | 621.00K | ||
| Net Income | -8.69M | ||
| Net Income Common Stock | -8.69M | ||
| Net Income Common Stock (USD) | -8.69M | ||
| Consolidated Income | -9.86M | ||
| Net Income to Non-Controlling Interests | -1.17M | ||
| Earnings per Basic Share | -0.10 | ||
| Earnings per Basic Share (USD) | -0.10 | ||
| Earnings per Diluted Share | -0.10 | ||
| Earning Before Interest & Taxes (EBIT) | -8.07M | ||
| Earning Before Interest & Taxes (USD) | -8.07M | ||
| Weighted Average Shares | 91.32M | ||
| Weighted Average Shares Diluted | 91.34M | ||
| Balance Sheet | |||
| Cash and Equivalents | 37.50M | ||
| Cash and Equivalents (USD) | 37.50M | ||
| Investments | 45.54M | ||
| Investments Current | 16.12M | ||
| Investments Non-Current | 29.42M | ||
| Trade and Non-Trade Receivables | 22.99M | ||
| Current Assets | 91.73M | ||
| Property, Plant & Equipment Net | 23.57M | ||
| Total Assets | 162.01M | ||
| Debt Current | 751.00K | ||
| Total Debt | 823.00K | ||
| Current Liabilities | 19.79M | ||
| Debt Non-Current | 72.00K | ||
| Total Liabilities | 25.03M | ||
| Accumulated Retained Earnings (Deficit) | -77.67M | ||
| Accumulated Other Comprehensive Income | 586.00K | ||
| Shareholders Equity | 101.31M | ||
| Shareholders Equity (USD) | 101.31M | ||
| Assets Non-Current | 70.28M | ||
| Total Debt (USD) | 823.00K | ||
| Deferred Revenue | 840.00K | ||
| Goodwill and Intangible Assets | 4.63M | ||
| Inventory | 11.35M | ||
| Liabilities Non-Current | 5.24M | ||
| Trade and Non-Trade Payables | 491.00K | ||
| Tax Assets | 7.72M | ||
| Tax Liabilities | 3.13M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 889.00K | ||
| Net Cash Flow from Financing | 21.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 431.00K | ||
| Capital Expenditure | -172.00K | ||
| Issuance (Purchase) of Equity Shares | 21.00K | ||
| Net Cash Flow from Investing | -3.05M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -2.88M | ||
| Net Cash Flow from Operations | 3.18M | ||
| Effect of Exchange Rate Changes on Cash | 285.00K | ||
| Share Based Compensation | 2.58M | ||